Chimeric Antidepressant Compounds Combining MARI and HDAC Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antidepressants, such as SSRIs, are not universally effective for depression and often cause significant side effects like GI distress and sexual dysfunction, with many patients experiencing drug resistance and a delay in therapeutic action.
Innovation Solution
Development of chimeric compounds comprising a monoamine reuptake inhibitor conjugated to a histone deacetylase inhibitor, such as fluoxetine or duloxetine linked to N-hydroxybenzamide, to create a multifunctional antidepressant with improved efficacy and reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If SSRIs are administered to treat depression, then antidepressant effect is achieved, but significant side effects occur including GI distress and sexual dysfunction
Solution Approach 1:
The patent combines a monoamine reuptake inhibitor (MARI) and a histone deacetylase inhibitor (HDACi) into a single chimeric compound through covalent bonding. This merging allows both therapeutic mechanisms to work synergistically within one molecule, achieving antidepressant effects through dual action while potentially reducing the need for separate medications and their associated side effects
Solution Approach 2:
The chimeric compound functions as a composite therapeutic agent, integrating two distinct pharmacological functionalities (MARI and HDACi) into one molecular structure. This composite approach enables the compound to exhibit properties of both parent compounds, addressing multiple pathological mechanisms of depression simultaneously
2Reliability
If current antidepressants are used, then some therapeutic effect is achieved, but many patients experience drug resistance
Solution Approach 1:
By combining MARI and HDACi mechanisms in one chimeric compound, the patent creates a multifaceted therapeutic approach that can overcome drug resistance through dual mechanism of action, targeting both neurotransmitter reuptake and epigenetic regulation pathways
Solution Approach 2:
The chimeric compound serves multiple therapeutic functions simultaneously: it acts as both a monoamine reuptake inhibitor and a histone deacetylase inhibitor, providing universal applicability across different depressive conditions and potentially overcoming resistance to single-mechanism treatments
3Reliability
If SSRIs are administered, then antidepressant action is achieved, but significant delay in onset of therapeutic action occurs
Solution Approach 1:
The HDACi component of the chimeric compound may initiate epigenetic modifications and gene expression changes that prepare neural circuits for faster response to antidepressant treatment, potentially reducing the delayed onset typical of conventional SSRIs
Solution Approach 2:
The dual mechanism action of the chimeric compound allows simultaneous engagement of fast-acting neurotransmitter reuptake inhibition and epigenetic modulation, potentially accelerating the overall therapeutic response compared to sequential or separate administration of single-mechanism agents
Data Source
AI summary
This disclosure relates to chimeric compounds and methods for managing neurological conditions. In certain embodiments, the compound comprises a chemical structure of a monoamine reuptake inhibitor conjugated to a chemical structure of a histone deacetylase inhibitor. In certain embodiments, this disclosure relates to methods of treating or preventing a neurological disorder, mental disorder or depression comprising administering an effective amount of a compound disclosed herein to a subject in need thereof.